Skip to main content
Haemato AG logo

Haemato AG — Investor Relations & Filings

Ticker · HAEK ISIN · DE000A289VV1 LEI · 529900Q3CGRYVCW7E340 F Wholesale and retail trade
Open in API
Filings indexed 188 across all filing types
Latest filing 2026-02-10 Annual Report
Country DE Germany
Listing F HAEK

About Haemato AG

https://haemato.de/en/start.html

Haemato AG is a pharmaceutical company focused on the specialty pharma market, concentrating on treatments for chronic diseases and high-priced therapies. The company's business activities include the development, acquisition, licensing, and distribution of a product portfolio that comprises innovative patent-protected medicines, biosimilars, and generics. The portfolio also extends to narcotics, including cannabis products, as well as over-the-counter (OTC) products and special cosmetics. Haemato AG's primary therapeutic areas of focus are HIV/AIDS, neurology, oncology, rheumatology, and ophthalmology.

Recent filings

Filing Released Lang Actions
Konzernabschluss zum Geschäftsjahr vom 01.01.2024 bis zum 31.12.2024
Annual Report Classification · 100% confidence The document is a comprehensive annual report for HAEMATO AG for the fiscal year 2024. It includes the 'Bericht des Aufsichtsrats' (Supervisory Board Report), 'Lagebericht' (Management Report), and references to the 'Konzernabschluss' (Consolidated Financial Statements). It provides detailed business analysis, economic context, and governance information. It is not a mere announcement (RPA) or a short regulatory filing (RNS), but the full annual reporting package. FY 2024
2026-02-10 German
Jahresabschluss zum Geschäftsjahr vom 01.01.2024 bis zum 31.12.2024
Annual Report Classification · 95% confidence The document is a 'Jahresabschluss' (Annual Financial Statement) for HAEMATO AG for the fiscal year 2024. It contains a balance sheet (Bilanz), notes (Anhang), and details on management and board members. While it is an annual financial document, it is a standalone financial statement filing rather than a comprehensive 10-K style annual report (which typically includes a management discussion and analysis, business overview, and risk factors). In the context of German corporate filings, this is classified as an Annual Report/Financial Statement. Given the provided categories, '10-K' is the most appropriate fit for a full annual financial report. FY 2024
2026-01-22 German
Konzernabschluss zum Geschäftsjahr vom 01.01.2023 bis zum 31.12.2023
Audit Report / Information Classification · 98% confidence The document is titled "Konzernabschluss zum Geschäftsjahr vom 01.01.2023 bis zum 31.12.2023" (Consolidated Financial Statements for the fiscal year from 01.01.2023 to 31.12.2023) and contains extensive sections like "LAGEBERICHT" (Management Report), detailed economic analysis ("Wirtschaftsbericht"), and industry-specific data (Pharmamarkt). This structure, covering a full fiscal year and providing comprehensive financial and operational details, strongly indicates an Annual Report. Although the German term 'Konzernabschluss' often corresponds to the financial statements part of a 10-K, in the context of required filings, a full annual report containing the management discussion and analysis (Lagebericht) is best classified as the equivalent of a 10-K, which covers the entire year's performance. FY 2023
2025-04-10 German
Jahresabschluss zum Geschäftsjahr vom 01.01.2023 bis zum 31.12.2023
Annual Report Classification · 95% confidence The document is a formal 'Jahresabschluss' (Annual Financial Statement) for HAEMATO AG for the fiscal year 2023. It contains detailed balance sheets (Aktiva/Passiva), notes to the financial statements (Anhang), and information regarding management and board members. While it includes a brief mention of a dividend decision at the end, the core of the document is the comprehensive annual financial reporting required under German HGB (Handelsgesetzbuch) standards. This fits the definition of an Annual Report (10-K) as it provides the official yearly financial performance and company activity. FY 2023
2025-01-15 German
Jahresabschluss zum Geschäftsjahr vom 01.01.2022 bis zum 31.12.2022
Audit Report / Information Classification · 98% confidence The document text contains detailed financial statements, including a Balance Sheet ('Bilanz') for the fiscal year ending 31.12.2022, notes ('Anhang') detailing accounting policies, asset development tables, and management sign-offs ('Schönefeld, den 06.04.2023 Patrick Brenske, Vorstand'). The content explicitly covers the full annual financial performance and structure, which aligns perfectly with the definition of an Annual Report (10-K in the US context, or the equivalent comprehensive annual financial statement in German regulatory filings). Although the document is in German and references HGB (German Commercial Code), the comprehensive nature of the financial reporting (Balance Sheet, notes, management declaration) strongly indicates a full annual financial report, which maps best to the '10-K' category among the provided options, as it is the definitive yearly report covering full financial performance. FY 2022
2024-09-26 German
Konzernabschluss zum Geschäftsjahr vom 01.01.2022 bis zum 31.12.2022
Annual Report Classification · 100% confidence The document is a 'Konzernabschluss' (Consolidated Financial Statement) for HAEMATO AG for the fiscal year 2022. It includes the 'Bericht des Aufsichtsrats' (Supervisory Board Report) and the 'Konzernlagebericht' (Group Management Report). Since it contains comprehensive financial reporting, management analysis, and audit information for a full fiscal year, it is classified as an Annual Report (10-K). FY 2022
2024-02-09 German

Browse filings by year

21 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.